3 Psychedelic Sector Leaders That Investors Need To Be Aware OfPsyched Wellness Announces New OTCQB Ticker: PSYCF2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private Placement

Technical420 Site Search

Returned 11 result(s).

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a…

MindMed’s Drug Delivery Business Is One That Psychedelic Sector Investors Need To Be Watching

November has been a great month for the psychedelic therapy industry and was highlighted by Oregon passing legislation to decriminalize psychedelics. Although many people view the industry as not legitimate, the psychedelic therapy sector is comprised of real businesses that are funded and are working on developing treatments for debilitating…

MindMed Is Setting The Pace For Top Tier Psychedelics Stocks

MindMed (NEO: MMED, OTCQB: MMEDF) is considered to be one of the top psychedelic therapy biotech companies and is an opportunity that our readers should be aware of. Last week, the psychedelic therapy biotech company recorded volatile price movements after raising more than $28 million (CAD) through a private placement…

MindMed Announces $25 Million Bought Deal Public Offering

Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) ("MindMed" or the "Company"), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the "Lead Underwriter") pursuant to which the Lead Underwriter has agreed, on behalf of a…

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

MindMed (NEO: MMED) (OTCQB: MMEDF), the leading psychedelic medicine biotech company, on the heels of filing a NASDAQ uplisting application, today announced a funding commitment to found and launch a clinical training program focused on psychedelic assisted therapies and psychedelic inspired medicines at NYU Langone Health, one of the nation's premier…

Mind Medicine Inc. Launches First Of Its Kind Clinical Trials Using Synergistic Psychedelic Compounds

After Champignon Brands was issued a cease trade order from the SEC, the entire psychedelic therapy sector came under pressure and this is a trend that we have been closely following. Although we believe that investors need to conduct significant due diligence and be selective when it comes to the…

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines and the University Hospital Basel's Liechti Lab are now combining MDMA and LSD in a groundbreaking Phase 1 clinical trial. The Phase 1 MDMA-LSD trial is scheduled to start in Q4 of this year in Basel, Switzerland.…

MindMed Developing IP For Personalized Psychedelic Assisted Therapies

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is developing technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient. The technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient's profile.…

5 Companies Leading The New Wave Of Therapeutics In The Psychedelic Sector

One of the most exciting trends in the market is related to the work that is being undertaken on the biotech side of the psychedelic industry. A few years ago, if I was told that the psychedelic market will be one of the next big opportunities, I most likely would…

MindMed Inks Deal With Switzerland University For Rights On LSD Research

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel. Exploring High-Dose LSD Treatment for Anxiety MindMed CEO JR Rahn told Benzinga that much emphasis has been placed…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link